




Initial Results From an Open-Label Phase 1b/2 Study of RP1 Oncolytic Immunotherapy in Solid Organ Transplant Recipients With Advanced Cutaneous Malignancies (ARTACUS)

Michael R. Migden¹, Wanxing Chai-Ho², Gregory A. Daniels³, Theresa Medina⁴, Trisha M. Wise-Draper⁵, Meenal Kheterpal⁶, Jennifer C. Tang⁷, Sherrif F. Ibrahim⁸, Diana Bolotin⁹, Claire Verschraegen¹⁰, Nathalie C. Zeitouni¹¹, Katy K. Tsai¹², Laxminarasimha Donthireddy¹³, Praveen K. Bommareddy¹³, Jeannie W. Hou¹³, Walter Hong¹³, Diwakar Davar¹⁴

¹MD Anderson Cancer Center, Houston, TX, USA; ²UCLA David Geffen School of Medicine, Los Angeles, CA, USA; ³Moore's Cancer Center, University of California San Diego, La Jolla, CA, USA; ⁴University of Colorado Cancer Center, Aurora CO, USA; ⁵Division of Hematology-Oncology, University of Cincinnati, Cincinnati, OH, USA; ⁶Department of Dermatology, Duke University Medical Center, Durham, NC, USA; ⁷University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA; ⁸Rochester Dermatologic Surgery, Victor, NY, USA; ⁹University of Chicago, Department of Medicine, Section of Dermatology, Chicago, IL, USA; ¹⁰Division of Medical Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; ¹¹University of Arizona College of Medicine and US Dermatology Partners, Phoenix, AZ, USA; ¹²Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA; ¹³Replimune, Inc., Woburn, MA, USA; ¹⁴UPMC Hillman Cancer Center, Pittsburgh, PA, USA

Background: Solid Organ Transplantation and Non-Melanoma Skin Cancer

- Non-melanoma skin cancer (NMSC) is the most common post-transplant malignancy in solid organ transplant (SOT) recipients and occurs at a 7–53x higher incidence vs the general population¹
 - >90% of NMSCs in SOT recipients are cutaneous squamous cell carcinoma (CSCC) or basal cell carcinoma^{1,2}
 - Systemic immune checkpoint blockade is contra-indicated in the setting of SOT-associated NMSC, given the documented risk of allograft rejection^{3,4}
- Optimal management of NMSC in SOT is not well established^{3,4}




^aStandardized incidence ratios were calculated by dividing the observed number of NMSC cases by the expected number of cases based on the general population.

1. Friman T, et al. *Int J Cancer*. 2022;150(11):1779-91. 2. Garrett G, et al. *JAMA Dermatol*. 2017;153(3):296-303. 3. Mittal A and Colegio O. *Am J Transplant*. 2017;17(10):2509-30.

4. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]). Squamous Cell Skin Cancer. Version 1.2024.

Background: RP1

- RP1 is an oncolytic immunotherapy (HSV-1) that expresses GM-CSF and a fusogenic glycoprotein (GALV-GP-R-)¹




- When used in combination with intravenous nivolumab, intratumoral RP1 demonstrated a high rate of deep and durable responses in non-SOT patients with advanced skin cancers (IGNYTE study)²


Objective: To assess the safety and efficacy of single-agent RP1 in SOT recipients with skin cancers (NCT04349436)

GALV-GP-R-, gibbon ape leukemia virus glycoprotein with the R sequence deleted; GM-CSF, granulocyte-macrophage colony-stimulating factor; hGM-CSF, human GM-CSF; HSV-1, herpes simplex virus type 1; ICP, infected cell protein; pA, polyA signal; SOT, solid organ transplant; X, denotes inactivation of viral protein.

1. Thomas S, et al. *J Immunother Cancer*. 2019;7(1):214. 2. Milhem M, et al. *J Clin Oncol*. 2022;40(suppl 16):9553.

Methods: Study Design



 **RP1 is administered via direct or ultrasound-guided IT injection into superficial, cutaneous, subcutaneous, or nodal solid tumors. Deep visceral solid organs or nonsolid tumors (eg, malignant pleural effusions, malignant ascites, cerebral spinal fluid, etc); solid tumors in the brain, bone, or spinal cord; or tumors in transplanted organs are not eligible for RP1 injection**

^aAfter 3 seronegative patients were enrolled, safety in this population was assessed by the SRC, who approved continued enrollment of seronegative patients. One cycle = 2 weeks. The treatment period is up to 52 weeks (one year).
C, cycle; CSCC, cutaneous squamous cell carcinoma; D, day; EOT, end of treatment; HSV-1, herpes simplex virus type 1; IT, intratumoral; PFU, plaque-forming unit; Q2W, every 2 weeks; SOT, solid organ transplant; SRC, safety review committee.

© American Association for Cancer Research

Methods: Key Eligibility Criteria and Endpoints

Key eligibility criteria

Inclusion

- Solid organ or hematopoietic cell transplant recipients with recurrent, locally advanced, or metastatic cutaneous malignancies including CSCC, BCC, Merkel cell carcinoma, and melanoma
- At least 1 measurable tumor ≥ 1 cm in longest diameter or ≥ 1.5 cm in shortest diameter for lymph nodes and injectable lesions that, in aggregate, comprise ≥ 1 cm in longest diameter
- ECOG PS ≤ 1 and adequate hepatic, renal, and hematologic function
- Stable allograft function including allograft cfDNA
- No more than 1 prior systemic therapy for cutaneous malignancy

Exclusion

- Prior treatment with an oncolytic therapy
- Active significant herpetic infections or prior complications of HSV-1 infection
- A history of transplant-related viral infections requiring treatment or modification to immunosuppression, such as BKV, EBV, or CMV, within 3 months of study entry
- Patients with visceral metastases
- Other active malignancy (other than the disease under study) within 3 years of the first dose of RP1

Key endpoints

Primary

- Investigator-assessed ORR per modified RECIST 1.1
- Safety and tolerability

Secondary

- Duration of response, complete response rate, disease control rate, and progression-free survival by investigator review; 1-year and 2-year overall survival rates
- Quality of life score (EORTC QLQ-C30)

Exploratory

- Biomarker analysis

Results: Patient Demographics and Baseline Characteristics

Characteristic	All patients (N = 27)
Age , years, median (range)	68.0 (48–86)
Male , n (%)	21 (77.8)
Race , n (%)	
White	26 (96.3)
Native Hawaiian/Pacific Islander	1 (3.7)
Allograft type , n (%)	
Kidney	22 (81.5)
Liver	4 (14.8)
Lung	1 (3.7)
Heart	0

Characteristic	All patients (N = 27)
Cutaneous malignancies , n (%)	
CSCC	24 (88.9)
MCC	3 (11.1)
Stage at study baseline , n (%)	
Locally advanced	15 (55.6)
Metastatic ^a	12 (44.4)
Primary tumor location , n (%)	
Skin	26 (96.3)
Lymph node	1 (3.7)

Data cutoff: September 18, 2023

^aPer protocol, metastatic to skin, soft tissue, or lymph nodes.
CSCC, cutaneous squamous cell carcinoma; MCC, Merkel cell carcinoma.

Results: Efficacy

	Evaluable patients ^a (N = 23)
Best overall response per modified RECIST 1.1	n (%)
CR	5 (21.7) ^b
PR	3 (13.0) ^c
SD	1 (4.3)
PD	14 (60.9)
ORR (CR + PR)	8 (34.8)
DCR (CR + PR + SD)	9 (39.1)


	Responders (n = 8)
Characteristics of responders	n
Tumor type	
CSCC	6
MCC	2
Stage at study baseline	
Locally advanced	6
Metastatic	2

^aEnrolled ≥3 months before the data cutoff; 4 patients who went off study for reasons unrelated to NMSC or RP1-related adverse events (1 death each from COVID-19, stroke, and pneumonia and 1 withdrawal because of injection pain) were excluded from the efficacy analysis. The median study follow-up time for all enrolled patients (N = 27) was 18.7 weeks as of September 18, 2023.

^bOne patient with CSCC also had CR of a new primary BCC, which appeared post baseline and was also treated with RP1.

^cOne PR could not be confirmed because the patient withdrew consent; all other responses are confirmed.

Results: Response Profile Over Time



^aA second primary skin cancer that developed on study was allowed to be treated with RP1, per protocol. ^bSecond primary malignancy. ^cWithdrew consent. BCC, basal cell carcinoma; CR, complete response; CSCC, cutaneous squamous cell carcinoma; MCC, Merkel cell carcinoma; PD, progressive disease; PR, partial response; SD, stable disease.

Results: Examples of Patients With Confirmed Response

Baseline

1142-0003
August 2022




September 2023 (13 months)




Complete response

1137-0002^a
March 2023



September 2023 (6 months)



Partial response

1135-0009
April 2023



June 2023 (2 months)



Complete response

^aRight paraspinal muscle metastasis at C1–C2 level.

Results: Examples of Patients With Confirmed Response

Baseline

1143-0002
May 2022



August 2022 (3 months)



Complete response

Best response

1143-0001
June 2021



December 2021 (6 months)



Complete response

1135-0001
July 2021



October 2021 (3 months)





Complete response

Results: Biomarkers

Patient 1142-003

CD8

PD-L1



- IHC analysis from tumor biopsies indicated influx of CD8+ T cells and upregulation of PD-L1 expression after treatment

CD8, cluster of differentiation 8; CR, complete response; D, day; IHC, immunohistochemistry; PD-L1, programmed death-ligand 1; SCR, screening.

Results: Safety Profile

All-grade TEAEs (>10% of patients), n (%)	All patients (N = 27)		
	Grade 1/2	Grade ≥3	Total
Fatigue	9 (33.3)	0	9 (33.3)
Chills	7 (25.9)	0	7 (25.9)
Pyrexia	7 (25.9)	0	7 (25.9)
Anemia	2 (7.4)	3 (11.1)	5 (18.5)
Blood creatinine increased	5 (18.5)	0	5 (18.5)
Nausea	5 (18.5)	0	5 (18.5)
Urinary tract infection	3 (11.1)	2 (7.4)	5 (18.5)
Decreased appetite	4 (14.8)	0	4 (14.8)
Diarrhea	4 (14.8)	0	4 (14.8)

All-grade TEAEs (>10% of patients), n (%)	All patients (N = 27)		
	Grade 1/2	Grade ≥3	Total
Headache	4 (14.8)	0	4 (14.8)
Injection-site pain	4 (14.8)	0	4 (14.8)
Cellulitis	2 (7.4)	1 (3.7)	3 (11.1)
Confusional state	3 (11.1)	0	3 (11.1)
Constipation	3 (11.1)	0	3 (11.1)
Facial pain	3 (11.1)	0	3 (11.1)
Hypercalcemia	3 (11.1)	0	3 (11.1)
Hyperglycemia	2 (7.4)	1 (3.7)	3 (11.1)
Sepsis	0	3 (11.1)	3 (11.1)
Tumor pain	2 (7.4)	1 (3.7)	3 (11.1)

- The most common TEAEs were fatigue (33.3%), chills (25.9%), and pyrexia (25.9%)
 - No evidence of allograft rejection
 - Seventeen patients had at least 1 grade ≥3 AE, all unrelated to RP1
 - Eight deaths were reported: disease progression (n = 3); pneumonia (n = 2); sepsis, stroke, and pulmonary hypertension (n = 1 each); none were related to RP1

Other grade 3 TEAEs were encephalopathy and hyperkalemia (n = 2 each) and COVID-19, cerebrovascular accident, hematuria, hypertension, hyponatremia, mental status changes, tumor hemorrhage, aspiration, calciphylaxis, infusion-related reaction, lipase increased, pneumonia aspiration, staphylococcal infection, and *Pseudomonas* wound infection (n = 1 each). Grade 4 TEAEs were sepsis, cerebrovascular accident, mental status changes, COVID-19 pneumonia, and seizure (n = 1 each). Grade 5 TEAEs were disease progression (n = 2) and sepsis, cerebrovascular accident, and COVID-19 pneumonia (n = 1 each). AE, adverse event; COVID-19, coronavirus disease 2019; TEAE, treatment-emergent AE.

Conclusions

- This is the first clinical trial assessing single-agent intratumoral RP1 in solid organ transplant patients on chronic immunosuppressive treatment with advanced skin cancer in whom systemic immunotherapy is typically contra-indicated
- RP1 monotherapy showed clear antitumor activity, with an ORR of 34.8% (5/23 [21.7%] confirmed CR) in evaluable patients, with most responses ongoing as of the data cutoff^a
- No allograft rejection was observed as of the data cutoff^a including in hepatic and lung allografts
- RP1 monotherapy was well tolerated, and the safety profile was similar to the profile in non-immunocompromised patients with advanced skin cancers (IGNYTE study)

^aSeptember 18, 2023.
CR, complete response; ORR, objective response rate.

Acknowledgments

- The authors would like to thank the patients, their families, and the site staff/investigators for their participation in the trial



ARTACUS is currently recruiting patients.
To learn more about enrolling your patient, contact clinicaltrials@replimune.com or +1 (781) 222 9570.



Additional information can be obtained by visiting [Clinicaltrials.gov](https://clinicaltrials.gov) (NCT04349436).